Formulary E-news :
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Formulary E-news
Modern Medicine Network
 
 
 
 
 
TOP SEARCHES: Alogliptin // PCI // Clopidogrel
In this issue
• CRP, statins
• FDA safety, transparency
• Smart pumps
• Multiple myeloma
Key Topic Updates

Survey

This month we would like to know...

Does your healthcare organization use IV smart pump technologies?

Vote in our survey, and see what other P&T committee members have to say.
Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

JULY 21, 2009
Elevated CRP alone does not justify statin treatment
C-reactive protein (CRP) does not add predictive value to traditional cardiovascular risk factors, and there does not appear to be a causal association between CRP and coronary heart disease (CHD), according to results of 2 studies published in the July 1, 2009, issue of the Journal of the American Medical Association. More...
FDA leaders stress safety, transparency in drug development
An important component in protecting public health, according to Margaret Hamburg, new commissioner of FDA, is to ensure access to innovative, safe, and effective medical products. Achieving the agency’s fundamental goals of promoting health, preventing illness, and prolonging life cannot be measured by the number of facilities inspected or new drugs approved, Hamburg and principal deputy commissioner Joshua Sharfstein stated in an editorial in the New England Journal of Medicine. More...
New IV smart pump technologies prevent medication errors, ADRs
Adverse drug reactions (ADRs) and the medication errors that cause them are an ongoing target of healthcare systems. The campaign for improved patient safety is advancing on several fronts as institutions stress better monitoring of patients and implement new technologies, such as bar coding of drugs and computerized physician order entry (CPOE). Leading the drive to improve medication safety is the need to develop safer systems for monitoring and delivering drugs. More...
Therapeutic considerations in managing multiple myeloma
Management strategies for multiple myeloma (MM) have continued to evolve as the result of innovative treatment modalities and efficacy data used in establishing new standards of care, including new combination therapy. MM continues to be one of the most costly cancers because of the need for stem cell transplant and medication used in initial and relapse stages, as well as in supportive care. This review highlights treatment guidelines, disease staging criteria, and new therapeutic approaches to MM, including an overview of supportive care and emerging pipeline agents. More...
 
Key Topic Updates
Medication Safety
FDA requires stronger label warnings about propoxyphene
Hormone replacement therapy linked to ovarian cancer
Antipsychotic drugs and mortality link explored
Ketamine appears safe for intubation in critical patients
ADHD medications may be linked to sudden unexplained death
Drug Pipeline/Clinical Updates
Famotidine may prevent peptic ulcers in patients taking aspirin
Stepped-dose efavirenz may minimize side effects
Single-dose versus split-dose treatment of colitis examined
HPV vaccine linked to high efficacy in neoplasia reduction
Bevacizumab may improve hearing in neurofibromatosis
Interferon gamma-1b no help to pulmonary fibrosis patients
Regulatory/Legislative
Obama backs public plan option for health reform
FDA issues guidance on PCIDs
Obama looks to expand power of Medicare advisory board

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.